New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 31, 2012
10:03 EDTBMY, PMFG, FBOn The Fly: Analyst Upgrade SummaryPMFG, Inc.
Today's noteworthy upgrades include: Bristol-Myers (BMY) upgraded to Neutral from Underweight at Atlantic Equities... Facebook (FB) upgraded to Outperform from Underperform at BMO Capital... PMFG, Inc. (PMFG) upgraded to Buy from Hold at Needham.
News For BMY;FB;PMFG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 >>
January 25, 2016
16:00 EDTFBOptions Update; January 25, 2016
Subscribe for More Information
15:12 EDTFBFacebook volatility increases into Q4 and outlook
Subscribe for More Information
12:05 EDTFBTwitter growth acceleration less likely in near-term, says Evercore ISI
Evercore ISI analyst Ken Sena says the likelihood of near-term growth reacceleration at Twitter (TWTR) looks less likely following today's executive departures. The analyst adds in an intraday research note that traffic trends and agency channel checks continue "to point to the worst" for the company. Sena lowered his Q4 estimates to the low-end of the company's guidance and cut his price target for the shares to $19 from $22. He continues to prefer Facebook (FB) and keeps a Hold rating on Twitter.
10:00 EDTBMYOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: American Eagle (AEO) downgraded to Hold from Buy at BB&T... American Express (AXP) downgraded on weak revenue outlook at Argus... Bristol-Myers (BMY) downgraded to Market Perform from Outperform at BMO Capital... Caterpillar (CAT) downgraded to Sell from Neutral at Goldman... Crestwood Equity (CEQP) downgraded to Neutral on potential distribution cut at Baird... Cummins (CMI) downgraded to Neutral from Buy at Citi... Federal Realty (FRT) downgraded to Hold from Buy at Evercore ISI... GKN PLC (GKNLY) downgraded to Neutral from Outperform at Credit Suisse... Galapagos NV (GLPG) downgraded to Neutral from Buy at GoldmanvHortonworks (HDP) downgraded to Perform from Outperform at Oppenheimer... International Flavors (IFF) downgraded on headwinds at Stifel... International Paper (IP) downgraded to Neutral from Buy at Citi... JPMorgan (JPM) downgraded to Neutral from Buy at Nomura... KapStone (KS) downgraded to Underperform from Neutral at Macquarie... Mosaic (MOS) downgraded to Neutral from Overweight at JPMorgan... NetSuite (N) downgraded to Equal Weight from Overweight at Stephens... ONEOK Partners (OKS) downgraded to Neutral at Baird... OvaScience (OVAS) downgraded to Perform from Outperform at Oppenheimer... Packaging Corp. (PKG) downgraded to Neutral from Buy at Citi... Potash (POT) downgraded to Neutral from Overweight at JPMorgan... Power Solutions (PSIX) downgraded to Neutral from Overweight at Piper Jaffray... Raymond James (RJF) downgraded to Neutral from Buy at Nomura... Regeneron (REGN) downgraded to Sell from Neutral at Chardan... SanDisk (SNDK) downgraded to Underperform from Outperform at CLSA... Toll Brothers (TOL) downgraded to Market Perform from Outperform at JMP Securities... Twitter (TWTR) downgraded to Hold from Buy at Stifel... WPX Energy (WPX) downgraded to Sector Perform from Outperform at Iberia... WestRock (WRK) downgraded to Neutral from Buy at BofA/Merrill... Whole Foods (WFM) downgraded to Underperform from Market Perform at BMO Capital... Zurich Insurance (ZURVY) downgraded to Neutral from Outperform at Exane BNP Paribas.
09:32 EDTFBApple Active equity options trading on open
Subscribe for More Information
08:27 EDTBMYBristol-Myers downgraded at BMO Capital
As noted earlier, BMO Capital downgraded Bristol-Myers to Market Perform from Outperform. The firm says that its positive thesis on clinical catalysts for the company's Opdivo drug has "mostly materialized." Target to $70 from $74.
08:04 EDTBMYAgilent's Dako announces FDA expanded approval of Dako PD-L1 IHC 28-8 pharmDx
Subscribe for More Information
07:40 EDTFBFBR sees constructive setup into Facebook earnings report
Subscribe for More Information
06:05 EDTBMYBristol-Myers downgraded to Market Perform from Outperform at BMO Capital
Subscribe for More Information
05:51 EDTFBOptions expected to be active: TYC JCI TWTR SUNE AAPL PG HAL AMZN FB
Subscribe for More Information
January 24, 2016
14:40 EDTFBCollapse in private tech could ripple into public markets, Barron's says
Subscribe for More Information
13:50 EDTBMYBristol-Myers says FDA expands indication for Opdivo-Yervoy
Bristol-Myers Squibb announced that the FDA has approved Opdivo, or nivolumab, in combination with Yervoy, or ipilimumab, for the treatment of patients with BRAF V600 wild-type and BRAF V600 mutation-positive unresectable or metastatic melanoma. "This indication is approved under accelerated approval based on progression-free survival. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials," the company noted. The approval expands the original indication for the treatment of patients with BRAF V600 wild-type unresectable or metastatic melanoma to include patients, regardless of BRAF mutational status, based on data from the Phase 3 CheckMate -067 trial. The FDA also expanded the use of Opdivo as a single-agent to include previously untreated BRAF mutation-positive advanced melanoma patients.
January 22, 2016
16:01 EDTFBActionable Options for Friday January 22
Subscribe for More Information
09:34 EDTFBActive equity options trading on open
Subscribe for More Information
09:29 EDTBMYOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: ABB (ABB) upgraded to Neutral from Sell at UBS... ACADIA (ACAD) upgraded to Overweight from Neutral at Piper Jaffray... ASML (ASML) upgraded to Hold from Sell at Deutsche Bank... Alaska Air (ALK) upgraded to Buy from Hold at Deutsche Bank... Arrow Electronics (ARW) upgraded to Buy from Neutral at Longbow... Avnet (AVT) upgraded to Buy from Neutral at Longbow... Avon Products (AVP) upgraded to Overweight from Neutral at Piper Jaffray... BankUnited (BKU) upgraded to Buy from Hold at Sandler O'Neill... Barclays (BCS) upgraded to Hold from Sell at Berenberg... Bristol-Myers (BMY) upgraded to Buy from Hold at Berenberg... CA Technologies (CA) upgraded to Buy from Neutral at Mizuho... CaixaBank (CAIXY) upgraded to Buy from Neutral at Nomura... Canadian Pacific (CP) upgraded to Outperform from Sector Perform at RBC Capital... Cardinal Financial (CFNL) upgraded to Outperform from Market Perform at Keefe Bruyette... Columbia Sportswear (COLM) upgraded to Outperform at Baird... Dr Pepper Snapple (DPS) upgraded to Outperform from Underperform at CLSA... Gorman-Rupp (GRC) upgraded to Outperform from Neutral at Boenning & Scattergood... Independent Bank (INDB) upgraded to Buy from Neutral at Compass Point... JD.com (JD) upgraded to Buy from Neutral at Nomura... KeyCorp (KEY) upgraded to Overweight from Equal Weight at Stephens... Lincoln National (LNC) upgraded to Strong Buy from Outperform at Raymond James... Masco (MAS) upgraded to Outperform at Baird... MetLife (MET) upgraded to Strong Buy from Market Perform at Raymond James... Northern Trust (NTRS) upgraded to Buy from Hold at Sandler O'Neill... Pacific Continental (PCBK) upgraded to Outperform at Keefe Bruyette... Qualcomm (QCOM) upgraded to Outperform from Market Perform at Northland... SL Green Realty (SLG) upgraded to Buy from Neutral at SunTrust... SVB Financial (SIVB) upgraded to Overweight from Neutral at Piper Jaffray... SunPower (SPWR) upgraded to Overweight from Equal Weight at Barclays... WEX Inc. (WEX) upgraded to Outperform from Market Perform at Wells Fargo.
08:36 EDTFBFacebook outlook positive, says Sterne Agee CRT
Subscribe for More Information
08:11 EDTBMYMerck price target lowered to $58 from $67 at Leerink
Leerink analyst Seamus Fernandez lowered his price target for Merck (MRK) to $58 citing his expectation for Bristol-Myers (BMY) to remain the leader in the immuno-oncology market as well as a "harder to penetrate" hepatitis C virus market. Nonetheless, the analyst believes headwinds facing Januvia, Keytruda and the HCV franchise are reflected in Merck shares at current levels. Fernandez keeps a Market Perform rating on the name.
07:13 EDTFBFacebook should report strong Q4 results, says Oppenheimer
Subscribe for More Information
06:31 EDTBMYLeerink recommends buying Bristol-Myers shares now
Leerink analyst Seamus Fernandez recommends buying shares of Bristol-Myers now saying the company's dominance of the immuno-oncology market "is likely to continue for at least the next several years." The analyst expects Bristol to see "substantial operating leverage" in the second half of 2016 as the company annualizes the loss of Abilify profits. He raised his price target for the shares to $78 from $77 and keeps an Outperform rating on the name.
06:07 EDTBMYBristol-Myers upgraded to Buy from Hold at Berenberg
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use